Vrushak Deshpande, MD
Gastroenterology · Port Orange, FLNPI 1003150715
Payments from drug & device makers
Across 490 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$883
- Phathom Pharmaceuticals, Inc.$484
- QOL Medical, LLC$470
- Gilead$372
- plus $4K from 26 others
What the payments were for
- Food & beverage$9,51399%
- Education$1181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 141 | $2,324 |
| Johnson & Johnson(2 entities) | 55 | $1,075 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 50 | $883 |
| Phathom Pharmaceuticals, Inc. | 7 | $484 |
| QOL Medical, LLC | 18 | $470 |
| Gilead | 12 | $372 |
| Madrigal Pharmaceuticals | 15 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $347 |
| Merck | 19 | $342 |
| Bristol Myers Squibb | 19 | $296 |
| Sanofi | 14 | $293 |
| Intercept Pharmaceuticals, Inc. | 13 | $259 |
| Ipsen Biopharmaceuticals, Inc | 9 | $237 |
| Nestle Healthcare Nutrition Inc. | 13 | $233 |
| Ardelyx, Inc. | 11 | $231 |
| Aimmune Therapeutics, Inc. | 10 | $221 |
| Ironwood Pharmaceuticals, Inc | 12 | $215 |
| Pfizer | 12 | $193 |
| Redhill Biopharma Inc. | 13 | $174 |
| Regeneron Healthcare Solutions, Inc. | 6 | $117 |
| Vivus LLC | 5 | $112 |
| Medtronic | 2 | $68 |
| Lilly USA, LLC | 3 | $62 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Braintree Laboratories, Inc. | 2 | $47 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Concordia Pharmaceuticals Inc. | 2 | $23 |
| Celltrion USA Inc. | 1 | $19 |
| Capsovision, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,631 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 15 | $233,761 |
| OcalivaObeticholic Acid | 11 | $100,906 |
| ZenpepLipase/Protease/Amylase | 11 | $46,482 |
| XifaxanRifaximin | 17 | $44,316 |
| LinzessLinaclotide | 53 | $41,686 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 59 | $9,912 |
| Omeprazole | 574 | $7,858 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 120 | $7,130 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 28 | $3,967 |
| Dexlansoprazole DrDexlansoprazole | 13 | $3,557 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 20 | $3,252 |
| Pantoprazole Sodium | 147 | $2,148 |
| Ursodiol | 13 | $1,482 |
| Colestipol Hcl | 12 | $994 |
| Esomeprazole Magnesium | 28 | $887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $470 | $233,76115 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $259 | $100,90611 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $883 | $48,28245 claims |
| Aimmune Therapeutics, Inc.Zenpep | $221 | $46,48211 claims |
| AbbVieLinzess | $2,324 | $41,68653 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $35 | $9,91259 claims |
| Braintree Laboratories, Inc.Sutab | $47 | $3,25220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Port Orange
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
- Paul HellsternCrystal River$4.5M
- Henry LevineOrlando$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.